New today“The son (Kunlunxin) is shopping a $50 billion valuation while the father's whole market cap is $36 billion — and subscribers must bundle 3–7x their allocation in chip orders; that's not an IPO, it's a group-buy. Enjoy the 'rich kid, proud parent' story as fiction — the tape cast its no vote this morning”
Score6/10This morning Down as much as 8%, leading HS Tech declinersKunlunxin valuation target $50B vs Baidu's ~$36B market capBundling clause Subscribers must buy 3–7x in chipsQ1 net income -55.3%Search ads -28.6% YoY
Technicals — Broke the 20-day (HK$109.8) on 2.26x volume this morning, touching HK$104.3 at the low. RSI at 40 is neutral-weak, and the 52-week low at HK$84.2 is still 20% below — neither oversold nor supported.
Fundamentals — AI revenue crossed half the mix (52%) for the first time, yet profit didn't follow: Q1 net income fell 55.3% and search ads bled 28.6% — faster than AI can transfuse. Kunlunxin is the most valuable asset on the books (China's #2 AI-chip shipper), but the more the spin-off succeeds, the more concrete the hollowed-parent worry becomes.
News — Kunlunxin is running a dual-track IPO (confidential HKEX filing plus STAR-board tutoring) with bank valuations wildly split ($16B–$57B), and the bundling clause has raised channel-stuffing questions. Baidu led HS Tech lower this morning with fellow model-play Zhipu down 10% — the other face of the AI-asset repricing.
Short-term · 1–3 weeks
NeutralSidelines
Heavy-volume panic, bleeding fundamentals and a contested spin-off price — three uncertainties stacked. On the left side your only friend is price, and this price isn't cheap enough yet.
Entry The HK$100 round number is the first watch level; skip every bounce until HK$110 (the 20-day) is reclaimedStop —Target —
Long-term · months+
Neutral
A sum-of-the-parts (Kunlunxin + cloud + Apollo) clearly covers the market cap, but the spin-off-discount-plus-bleeding-core combination has rarely paid shareholders; settle the full bill after Kunlunxin prices.
Search-ad bleed outpacing AI transfusion
Kunlunxin IPO pricing or timeline disappointing
Beta to a broad AI-model-stock ebb
Community Voices
东财股吧 · The 'proud parent' and 'selling the son to fund retirement' camps are at war — retail is really arguing one question: after the chip unit lists, what's left of BaiduOriginal ↗
Institutional Views
华尔街共识 · 18 analysts average HK$179.5 — 69% above spot; the chasm between consensus and tape is itself the answer to the position question
高盛（转引） · Benchmarked to Cambricon, Baidu's Kunlunxin stake is worth a lot on paperSource ↗
澎湃新闻 · Kunlunxin's assets and baggage: #2 domestic shipper, deeply tied to Baidu's own demandSource ↗
New today“The CXO duo has one name printing highs and the other pressed against them — Asymchem is up 39% in a month with HK$130 one kick away. There's no shame in buying a breakout; the shame is buying one without a stop. Below HK$115, this story is no longer yours”
Score7/101-month +38.7%To 52-wk high HK$130 — one step awayRSI(14) 66.8Sector echo WuXi Bio (2269, held) printing highs in tandemBank target avg HK$136.1
Technicals — A fully bullish MA stack (20-day HK$108, 50-day HK$101, 200-day HK$89), with this morning's 4.9% push on 1.24x volume pressing the HK$130 prior high. This isn't a one-day melt-up chase — it's a month of stair-step gains, and RSI at 66.8 is warm, not burnt.
Fundamentals — CXO demand is flowing back — innovative-drug licensing plus a warming peptide/small-molecule order cycle has made interim-season order visibility a safe-harbor theme for HK money. The July 8 H-share incentive grant (at RMB 1.00) locks in the core team.
News — Shares rose 6.7% on July 9 when the incentive grant was disclosed; with WuXi Bio printing highs in tandem, CXO is one of the few long themes on a red tech tape. Two bank buy ratings in 90 days, average target HK$136.1.
Short-term · 1–3 weeks
LongLean bullish
Breakout channel, sector confirmation (2269 at highs too) and a stair-step monthly climb — triple confirmation. The HK$115 stop allows 1.5 ATRs (HK$8.75); a break means being wrong, and the entire dignity of new-high trading lives in the stop.
Entry Scale in inside HK$122–128; a volume close above HK$130 confirms the breakoutStop HK$115Target HK$145
Long-term · months+
Accumulate
A warming CXO cycle with rising utilization, big order elasticity in peptides (GLP-1 spillover), and the RMB-1 incentive grant aligning management.
雪球 · CXO chatter is heating up — bagholders from the last cycle top are still lecturing new buyers, which is the standard soundtrack of an advance's first halfOriginal ↗
Institutional Views
华尔街共识 · 7 analysts average HK$133 — 4.2% above spot at a 1.07 rating; targets are being chased higher by the price
搜狐财经 · H-share incentive granted; two buy ratings in 90 days with an average target of HK$136.1Source ↗
+10.77%07-02“After a 15% week, one flat day is a rest, not a reversal — and closing flat while HS Tech bled is independence worth more than the gain itself; with the stop lifted above cost, others fight vertigo while you just read the ledger”
Technicals — A quiet consolidation after the 15% week: the 7-day RSI at 74.8 is short-term hot but the daily RSI of 56 is healthy. The 20-day sits far below at HK$101.4 with the 50-day at HK$116.8 as the next gate. Flat this morning against a falling tech index — relative strength intact.
Fundamentals — The FY27Q1 preview points to cloud growth accelerating to ~45% (above expectations) with EBITA margin reaching low double digits; Qwen 4.0 plus the QoderWork/Wukong/MuleRun productivity suite gives the 'reprice AI assets' narrative something real to hold.
News — After the two-stage jump (+12% on 7/8, +5% on 7/9), rotation has settled in and the banks' 'time to reprice AI assets' call keeps working; a flat close on a red HS Tech morning says the holder base hasn't loosened.
Short-term · 1–3 weeks
LongBullish
Low-volume consolidation after a surge is a bullish shape, counter-tape strength is valuable, and the stop already sits above cost — this is the textbook let-it-run setup, not a take-profit one.
Entry Hold; a pullback to HK$105–107 remains the only dignified boarding zone for those who missed itStop HK$105Target HK$130
Long-term · months+
Accumulate
The cloud+AI re-rating is still early with a valuation discount to US peers as the cushion; core-commerce cash flow funds the capex cycle.
LLM monetization underdelivering
Regulatory whiplash
Weak consumption dragging the core
Signal BacktestCumulative +10.77%price itself +17.75%0/1 closed trades wonprofitable since 07-09
07-02LongHK$94.5 → closed HK$94.107-04-0.42%
07-08LongHK$99.6 → open → HK$110.8+11.24%
Community Voices
雪球 · The 'phase two of the AI re-rating' camp battles the 'take the money' camp — the sidelined wait for a dip, and a dip that never comes is the market's cruelest trickOriginal ↗
0.00%07-09“An RSI of 26.8 on a stock already halved in three months can still fall another thirty percent — with CATL's mine restarting and West Africa ramping, supply-side bad news is a rainy season, and you don't step out before seeing an umbrella (volume drying up into a base); this morning's +2.8% was just a minute spent under the eaves”
Score5/10RSI(14) 26.8Week / month / 3M -15.6% / -30.5% / -49.9%Lithium carbonate RMB 205k → 147k per tonneSupply side CATL mine restarting + West Africa's largest mine onstreamConsensus target HK$85.7 (+105%)
Technicals — Every average points down and price sits 29% below the 200-day; this morning's 2.8% uptick is an RSI-26 technical gasp on 0.8x volume — even the bounce drew no crowd. The 52-week low at HK$23.8 is a reminder of how much room remains below.
Fundamentals — The earnings-vs-price rift: volume growth plus hedging may keep the interim report respectable, but the market is pricing 2027 oversupply — Goldman sees the lithium market tipping into surplus in H2, so earnings-delivery day doubles as money-exit day.
News — Tianqi's A-shares limit-downed on July 8 as supply-increase headlines hammered the sector; NBD reports money voting with its feet just as lithium earnings deliver. This morning HK lithium bounced together (Tianqi +3.3%) — the weekly wounds are nowhere near healed.
Short-term · 1–3 weeks
NeutralSidelines
Oversold guarantees bounce elasticity, not a reversal. Oversupply gets priced over quarters, and every day on the left side has more patience than you do.
Entry Three conditions, no exceptions: volume below 0.7x, the weekly chart stabilizing, and lithium futures basing; below the HK$40 round number, HK$35 is nextStop —Target —
Long-term · months+
Neutral
Global resource depth plus vertical integration make this next-cycle bottom inventory — but the left side is long; talk allocation only after supply-clearing signals (curtailments, bankruptcies, capex collapse).
Deepening surplus and a second leg down in lithium prices
Twin selling pressure across A and H shares
Hedging gains masking spot deterioration
Community Voices
雪球 · Cries of 'lithium is being slaughtered' flood the feed — retail counts bottoms while the bottom counts retailOriginal ↗
Institutional Views
华尔街共识 · 11 analysts average HK$85.7 — 105% above spot; that's a relic of the last cycle, don't anchor to it
高盛（转引） · Sees the lithium market in surplus in H2Source ↗
每日经济新闻 · Lithium stocks grow earnings while money walks; supply additions cap the multipleSource ↗
Up 9.5% this morning at HK$689.00, a V-snapback the day after the cornerstone lock-up (7/13) landed — bad-news-spent buying, but a -16.9% week of roller coaster isn't for weak hearts
Up 3.3% this morning at HK$230.00 — a technical gasp after the lock-up halving; of the three conditions (volume dry-up, base, 20-day reclaim), zero are met — keep waiting
Up 3.3% this morning at HK$34.16, breathing in sync with Ganfeng — at 13–15x forward it's the cheaper twin, but cheap has never stopped a lithium price from falling; sidelines
